Von Willebrand Disease News and Research

RSS
Von Willebrand disease (VWD) is a bleeding disorder. It affects your blood's ability to clot. If your blood doesn't clot, you can have heavy, hard-to-stop bleeding after an injury. The bleeding can damage your internal organs or even cause death, although this is rare.

In VWD, you either have low levels of a certain protein in your blood, or the protein doesn't work the way it should. The protein is called von Willebrand factor, and it helps the blood clot.
Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

New drug approved by FDA for treatment of von Willebrand disease

New drug approved by FDA for treatment of von Willebrand disease

FDA approves recombinant von Willebrand factor for treating bleeding episodes in adults with VWD

FDA approves recombinant von Willebrand factor for treating bleeding episodes in adults with VWD

First patient enrolled in CSL Behring's rVIIa-FP Phase II/III study to treat patients with hemophilia A or B with inhibitors

First patient enrolled in CSL Behring's rVIIa-FP Phase II/III study to treat patients with hemophilia A or B with inhibitors

Engineered protein shown effective in patients with severe von Willebrand disease

Engineered protein shown effective in patients with severe von Willebrand disease

CSL Behring awarded NHF's 2015 Corporate Leadership Award

CSL Behring awarded NHF's 2015 Corporate Leadership Award

Global haemophilia therapeutics market estimated to reach $13.43 billion in 2019

Global haemophilia therapeutics market estimated to reach $13.43 billion in 2019

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

CSL Behring donates protein therapies to World Federation of Hemophilia

CSL Behring donates protein therapies to World Federation of Hemophilia

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

CSL Behring strengthens global manufacturing capabilities to meet demand for lifesaving therapies

CSL Behring strengthens global manufacturing capabilities to meet demand for lifesaving therapies

School nurses reach 98% of students in U.S. public schools to diagnose primary immunodeficiency

School nurses reach 98% of students in U.S. public schools to diagnose primary immunodeficiency

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

Baxter reports topline results from BAX 111 Phase 3 trial for treatment of von Willebrand disease

Baxter reports topline results from BAX 111 Phase 3 trial for treatment of von Willebrand disease

CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

EMA expands administration options for Hizentra

EMA expands administration options for Hizentra